Please use this identifier to cite or link to this item:
Title: Oncogenic regulation of tumor metabolic reprogramming
Author: Tarrado Castellarnau, Míriam
Atauri Carulla, Ramón de
Cascante i Serratosa, Marta
Keywords: Cèl·lules canceroses
Cancer cells
Issue Date: 28-Jul-2016
Publisher: Impact Journals
Abstract: Development of malignancy is accompanied by a complete metabolic reprogramming closely related to the acquisition of most of cancer hallmarks. In fact, key oncogenic pathways converge to adapt the metabolism of carbohydrates, proteins, lipids and nucleic acids to the dynamic tumor microenvironment, conferring a selective advantage to cancer cells. Therefore, metabolic properties of tumor cells are significantly different from those of non-transformed cells. In addition, tumor metabolic reprogramming is linked to drug resistance in cancer treatment. Accordingly, metabolic adaptations are specific vulnerabilities that can be used in different therapeutic approaches for cancer therapy. In this review, we discuss the dysregulation of the main metabolic pathways that enable cell transformation and its association with oncogenic signaling pathways, focusing on the effects of c-MYC, hypoxia inducible factor 1 (HIF1), phosphoinositide-3-kinase (PI3K), and the mechanistic target of rapamycin (mTOR) on cancer cell metabolism. Elucidating these connections is of crucial importance to identify new targets and develop selective cancer treatments that improve response to therapy and overcome the emerging resistance to chemotherapeutics.
Note: Reproducció del document publicat a:
It is part of: Oncotarget, 2016, vol. 7, num. 38, p. 62726-62753
Related resource:
ISSN: 1949-2553
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Files in This Item:
File Description SizeFormat 
665211.pdf3.11 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons